drugset
Drugs / BI 44370
last change Jun 2009 re-read 2 minutes ago

BI 44370

also known as BI 44370 TA · BI 44370 BS · J3.353.239C

Small molecule targets CALCRL via inhibition

Developed for
migraine disorder
Investigated by
Boehringer Ingelheim

Trials 8 · a red edge is where a trial was stopped

today NCT02215759 · Ph 1 NCT00743015 · Ph 1 NCT02215772 · Ph 1 NCT02215031 · Ph 1 NCT00751803 · Ph 2 NCT02217514 · Ph 1 NCT02215746 · Ph 1 NCT02215018 · Ph 1
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT02215759 Jan → Jun 2009 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT00743015 Sep 2008 → Mar 2009 migraine disorder Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02215772 Sep → Oct 2008 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02215031 Sep → Nov 2008 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02217514 Feb → Mar 2008 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02215746 Jan → Apr 2008 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02215018 Apr → Aug 2007 — Boehringer Ingelheim Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00751803 Aug 2008 → May 2009 migraine disorder Boehringer Ingelheim Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as BI 44370 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02215746 ↗
3

NCT02217514 ↗

NCT02215031 ↗

NCT00743015 ↗
Known as BI 44370 BS ClinicalTrials.gov intervention name — accepted as the source's own label NCT02215772 ↗
Known as BI 44370 TA ClinicalTrials.gov intervention name — accepted as the source's own label NCT02215759 ↗
2

NCT02215018 ↗

NCT00751803 ↗
Known as J3.353.239C ChEMBL registry synonym — accepted as the source's own label CHEMBL3334624 ↗
Action Inhibit “Calcitonin gene-related peptide type 1 receptor antagonist” CHEMBL3334624 ↗
Modality Small molecule — CHEMBL3334624 ↗
Route Oral “Relative Bioavailability Following Single Oral Administration of 200 mg of BI 44370 During and Between Migraine Attacks in Male and Female Migraine Patients. An Open-label,...” NCT00743015 ↗
Target CALCRL “Calcitonin gene-related peptide type 1 receptor antagonist” CHEMBL3334624 ↗